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A B S T R A C T
Background
Reduction or modification of dietary fat can improve total cholesterol levels, but may also have a variety of effects, both positive and
negative, on other cardiovascular risk factors.
Objectives
The aim of this systematic review was to assess the effect of reduction or modification of dietary fats on total and cardiovascular mortality
and cardiovascular morbidity over at least 6 months, using all available randomized clinical trials.
Search strategy
The Cochrane Library, MEDLINE, EMBASE, CAB Abstracts, CVRCT registry and related Cochrane Groups’ trial registers were
searched through spring 1998, SIGLE to January 1999. Trials known to experts in the field and biographies were included through
May 1999.
Selection criteria
Trials fulfilled the following criteria: 1) randomized with appropriate control group, 2) intention to reduce or modify fat or cholesterol
intake (excluding exclusively omega-3 fat interventions), 3) not multi factorial, 4) healthy adult humans, 5) intervention at least
six months, 6) mortality or cardiovascular morbidity data available. Inclusion decisions were duplicated, disagreement resolved by
discussion or a third party.
Data collection and analysis
Rate datawere extracted by two independent reviewers andmeta-analysis performed using random effectsmethodology.Meta-regression
and funnel plots were used.
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Main results
Twenty seven studies were included (40 intervention arms, 30,901 person-years). There was no significant effect on total mortality
(rate ratio 0.98, 95% CI 0.86 to 1.12), a trend towards protection form cardiovascular mortality (rate ratio 0.91, 95% CI 0.77 to
1.07), and significant protection from cardiovascular events (rate ratio 0.84, 95% CI 0.72 to 0.99). The latter became non-significant
on sensitivity analysis.
Trials where participants were involved for more than 2 years showed significant reductions in the rate of cardiovascular events and a
suggestion of protection from total mortality. The degree of protection from cardiovascular events appeared similar in high and low
risk groups, but was statistically significant only in the former.
Authors’ conclusions
The findings are suggestive of a small but potentially important reduction in cardiovascular risk in trials longer than two years. Lifestyle
advice to all those at high risk of cardiovascular disease (especially where statins are unavailable or rationed), and to lower risk population
groups, should continue to include permanent reduction of dietary saturated fat and partial replacement by unsaturates.
P L A I N L A N G U A G E S U M M A R Y
Cutting down or changing the fat we eat may reduce our risk of heart disease
Cutting down how much fat we eat or replacing some saturated (animal) fats by plant oils and unsaturated spreads may reduce risk
of heart disease, probably including fatal heart disease. Heart disease includes heart attacks, chest pain, strokes and the need for heart
surgery. This change in how we eat seems to protect us better if we stick to it for at least two years. People who already have heart
disease, and those who do not have heart disease, benefit in the same way.
B A C K G R O U N D
There has been a great deal of research carried out in the area of diet
and cardiovascular disease, the diet-heart hypothesis. Much of this
has been invested in long term prospective observational studies
looking at dietary patterns and subsequent cardiovascular events.
This work is powerful at providing associations between dietary
factors and cardiovascular risk. However, intervention studies are
needed to clarify cause and effect, and it is essential that interven-
tion trials form the basis of evidence based practice in this area.
Most intervention studies which have been carried out have stud-
ied the effect of dietary interventions on risk factors for heart dis-
ease, and separate work ties the effect of altering these risk factors
to changes in disease incidence and mortality. Systematic review
in this area follows the same pattern, so that there are reviews of
the effect of dietary advice on change on lipid levels (Brunner
1997; Clarke 1997; Denke 1995; Mensink 1992) and reviews
on the effect of lipid level alterations on cardiovascular morbid-
ity and mortality (Law 1994; Walsh 1995; Rubins 1995). Other
risk factors dealt with in a similar way are blood pressure mea-
surements (Bucher 1996; Law 1991), body weight (SIGN 1996),
angiographic measurements (Marchioli 1994), antioxidant intake
(Ness 1997) and alcohol (Rimm 1996).
A problem with this two-level approach is that any single dietary
alteration may have effects over a wide range of risk factors for
cardiovascular disease. An example of this is the choice of substi-
tution of saturated fats by carbohydrate, polyunsaturated fats or
monounsaturated fats in the diet. This choice will strongly affect
lipid profile, and may also affect oxidative state, rate of cholesterol
efflux from fibroblasts, blood pressure, weight, insulin resistance,
post-prandial triacylglycerol response, blood clotting factors and
platelet aggregation. There may also be other effects which we are
not yet aware of. Evidence of beneficial effect on one risk factor
does not rule out an opposite effect on another unstudied risk
factor, and therefore an overall null (or harmful) effect of inter-
vention. The best way of combining the effects on all of these risk
factors is to not study risk factors, but to study the effects of dietary
change on important outcomes, on cardiovascular morbidity and
mortality, and on total mortality.
The most commonly advised and studied dietary intervention for
protection against cardiovascular disease is the low or modified fat
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diet which aims to modify serum lipid levels. This has crystallized
as the American Heart Association Step 1 and 2 diets. These still
form the basis of more extensive dietary recommendations by the
American Heart Association (Stone 1996; Krauss 1996). How ef-
fective are these alterations in dietary fat at reducing cardiovascular
morbidity and mortality?
O B J E C T I V E S
The aim of this systematic review was to assess the effect of change
in dietary fats, which would be expected to result in lipid lower-
ing, on mortality and cardiovascular morbidity, using all available
randomized clinical trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials only. Randomization of individuals
was accepted, or of larger groups where there were at least 6 of
these groups randomized. Randomization was excluded where it
was clear that allocation concealment did not occur (e.g. divisions
based on days of the week or first letter of the family name were
excluded).
Types of participants
Studies of adults (18 years or older, no upper age limit) at any risk
of cardiovascular disease (with or without existing cardiovascular
disease) were accepted. Participants could be of either gender, but
those who were acutely ill, pregnant or lactating were excluded.
Types of interventions
All randomized controlled trials of interventions stating an inten-
tion to reduce or modify dietary fat or cholesterol, such as would
be expected to result in improvement of serum lipid profile, were
considered. The intervention had to be dietary advice, supplemen-
tation (of fats, oils or modified or low fat foods) or a provided diet,
and the control group usual diet, placebo or a control diet. Inter-
ventions excluded (unless they were present in addition to those
above) were addition of alpha-linolenic acid, omega-3 fats or fish
oils (as the mechanism of action of these fats is probably mainly
anti-thrombotic or anti-arrhythmic), high fibre diets and garlic (as
pulses, fruits and vegetables may have various effects other than
lipid lowering), low calorie diets or exploration of varying forms
of carbohydrate (unless also specifically low in fat or fat modified).
Also excluded were all multiple risk factor interventions other than
diet or supplementation (unless the effects of diet or supplemen-
tation could be separated).
Trials were only included where primary outcome data (mortality
or cardiovascular morbidity) could be collected (by communica-
tion with authors if necessary).
Types of outcome measures
Primary outcomes:
The main outcomes were total and cardiovascular mortality. The
other important outcome was combined cardiovascular events,
which included any of the following data available from a trial:
cardiovascular deaths, cardiovascular morbidity (non-fatal my-
ocardial infarction, angina, stroke, heart failure, peripheral vascu-
lar events) and unplanned cardiovascular interventions (coronary
artery bypass surgery or angioplasty).
Secondary outcomes:
Secondary outcomes included risk factor changes (weight, blood
pressure, total, LDL or HDL cholesterol and triglyceride levels)
and quality of life measures (feelings of health, time off work).
Search methods for identification of studies
The following sources have been included in the literature search
process. The Cochrane Library, MEDLINE, EMBASE, CAB Ab-
stracts, CVRCT Registry, SIGLE, bibliographies and experts. A
comprehensive search strategy was developed to search for nutri-
tion based randomized controlled trials with morbidity or mor-
tality outcomes. This search strategy was used for this review and
will be used for subsequent reviews.
MEDLINE on SilverPlatter was searched for randomized con-
trolled trials on diet and cardiovascular disease or mortality from
1966 to May 1998 with the following search strategy:
explode “NUTRITION”/adverse-effects , classification , con-
traindications , drug-effects , education , mortality , methods ,
nursing , physiology , utilization
explode “DIET”/ adverse-effects , blood , contraindications , drug-
effects , metabolism , mortality , methods , nursing , physiology ,
utilization
explode “DIET-THERAPY”/ all subheadings
explode “LIPIDS”/ administration-and-dosage , adverse-effects ,
therapeutic-use
explode “FOOD”/administration-and-dosage , adverse-effects ,
drug-effects , therapeutic-use
explode “VITAMINS”/administration-and-dosage , adverse-ef-
fects , therapeutic-use
“SELENIUM”/administration-and-dosage , adverse-effects , ther-
apeutic-use
“CALCIUM”/administration-and-dosage , adverse-effects , ther-
apeutic-use
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explode “CHLORIDES”/administration-and-dosage , adverse-ef-
fects , therapeutic-use
“MAGNESIUM”/administration-and-dosage , adverse-effects ,
therapeutic-use
“PHOSPHORUS,-DIETARY”/ all subheadings
“POTASSIUM,-DIETARY”/ all subheadings
explode “SODIUM-CHLORIDE”/ all subheadings
explode “TRACE-ELEMENTS”/administration-and-dosage , ad-
verse-effects , therapeutic-use
explode “FLUORIDES”/administration-and-dosage , adverse-ef-
fects , therapeutic-use
MEDITERRAN* in TI,AB
explode “ANTIOXIDANTS”/administration-and-dosage , ad-
verse-effects , therapeutic-use
#1 or #2 or #3 or #4 or #5 or #6 or #7
#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #
17
#18 or #19
LIPID* near (LOW* or REDUC* or MODIFI*)
DIET* in TI,AB
FAT* near (LOW* orMODIFI* or ANIMAL* or VEGETABLE*
or ACID* or MONO?UNSAT* or POLY?UNSAT* or SATU-
RAT* or UNSATUR*)
OIL* near (VEGETABLE* orOLIVE* orRAPE* or SUNFLOW*
or LINSEED* or MONO?UNSAT* or POLY?UNSAT* or SAT-
URAT* or UNSATUR*)
MEAT* in TI,AB
WEIGHT* near (REDUC* in TI,AB)
SLIMM* in TI,AB
FISH in TI,AB
ANTI?OXIDA* in TI,AB
VITAMIN* in TI,AB
MINERAL* in TI,AB
SALT* in TI,AB
SODIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAP-
SUL* or TABLET* or HIGH* or LOW* or ENRICH*)
VEGETABLE* in TI,AB
FRUIT* in TI,AB
POTASSIUM* near (ORAL* or SUPPLEMEN* or ADD* or
CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
LEGUM* in TI,AB
SOY* in TI,AB
#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or
#30
#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38
#39 or #40
OAT* in TI,AB
FOLIC* in TI,AB
FOLATE* in TI,AB
IRON* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL*
or TABLET* or HIGH* or LOW* or ENRICH*)
FERROUS* in TI,AB
FERRIC* in TI,AB
MARG?RINE* in TI,AB
BUTTER* in TI,AB
STARCH* in TI,AB
GRAIN* in TI,AB
NUT in TI,AB
NUTS in TI,AB
CAFFEIN* in TI,AB
COFFEE* in TI,AB
MULTI?VITAMIN* in TI,AB
CALCIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAP-
SUL* or TABLET* or HIGH* or LOW* or ENRICH*)
SELENIUM* near (ORAL* or SUPPLEMEN* or ADD* orCAP-
SUL* or TABLET* or HIGH* or LOW* or ENRICH*)
MAGNESIUM* near (ORAL* or SUPPLEMEN* or ADD* or
CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
MANGANESE* near (ORAL* or SUPPLEMEN* or ADD* or
CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
RETINOL* in TI,AB
CAROTENE* in TI,AB
BETA?CAROTENE* in TI,AB
THIAMIN* in TI,AB
RIBOFLAV* in TI,AB
PYRIDOXIN* in TI,AB
ASCORB* in TI,AB
TOCOPHEROL* in TI,AB
ALPHA?TOCOPHER* in TI,AB
MOLYBDENUM* in TI,AB
COBALAMIN* in TI,AB
BIOTIN* in TI,AB
FOLACIN* in TI,AB
NIACIN* in TI,AB
NICOTINIC* in TI,AB
PANTOTHEN* in TI,AB
PHOSPHORUS* near (ORAL* or SUPPLEMEN* or ADD* or
CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
CHROMIUM* near (ORAL* or SUPPLEMEN* or ADD* or
CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
COBALT* in TI,AB
IODINE* near (ORAL* or SUPPLEMEN* or ADD* or CAP-
SUL* or TABLET* or HIGH* or LOW* or ENRICH*)
GARLIC* in TI, AB
ZINC* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL*
or TABLET* or HIGH* or LOW* or ENRICH*)
#42 or #43 or #44 or #45 or #46 or #47
#48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or
#57
#58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or
#67
#68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or
#77
#78 or #79 or #80 or #81 or #82
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#20 or #41 or #83 or #84 or #85 or #86 or #87
explode “CARDIOVASCULAR-DISEASES”/ complications ,
diet-therapy , epidemiology , etiology , mortality , prevention-
and-control , rehabilitation , secondary , therapy
explode “CEREBROVASCULAR-DISORDERS”/ complica-
tions , diet-therapy , epidemiology , etiology , mortality , preven-
tion-and-control , rehabilitation , therapy
explode “NEOPLASMS”/ diet-therapy , mortality , prevention-
and-control
CORONARY* near (BYPAS* or GRAFT* or DISEASE* or
EVENT*)
CEREBRO?VASCULA*
CARDIO?VASC*
MYOCARDIAL* near (INFARCT* or RE?VASCULAR* or
ISCH?EMI*)
MORTAL*
MORBID* near (HEART* or CORONARY* or ISCH?EM* or
MYOCARD*)
VASCULAR* near (PERIPHERAL* or DISEASE* or COMPLI-
CATION*)
ANGINA*
STROKE*
HEART* near (DISEASE* or ATTACK* or BYPASS*)
#91 or #92 or #93 or #94 or #95 or #96 or #97 or #98 or #99 or
#100 or #101 or #89 or #90
#102 and #88
(TG=ANIMAL) not ((TG=HUMAN) and (TG=ANIMAL))
RANDOMIZED-CONTROLLED-TRIAL in PT
CONTROLLED-CLINICAL-TRIAL in PT
RANDOMIZED-CONTROLLED-TRIALS
RANDOM-ALLOCATION
DOUBLE-BLIND-METHOD
SINGLE-BLIND-METHOD
#107 or #108 or #109 or #110 or #105 or #106
#103 not #104
explode “CHILD”/ all subheadings
explode “ADULT”/ all subheadings
#113 and #114
#113 not #115
111 and #112
#117 not #116
AnadditionalMEDLINE (SilverPlatter 1966 to June 1998) search
strategy was run to collect papers where only lipid outcomes were
mentioned.
diet* in TI,AB
fib?r* in TI,AB
“Diet,-Atherogenic”
“Diet,-Fat-Restricted”/ all subheadings
explode “Fats”/ all subheadings
explode “Fatty-Acids”/ all subheadings
explode “Oils”/ all subheadings
explode “Dairy-Products”/ all subheadings
explode “Dietary-Fats”/ all subheadings
“Dietary-Fiber”/ all subheadings
“Food,-Fortified”/ all subheadings
explode “Nuts”/ all subheadings
lipid* near (low* or reduc* or modif*)
fat* near (diet* or low* ormodifi* or animal* or vegetable* or acid*
or mono?unsat* or poly?unsat* or saturat* or unsatur*)
oil* near (vegetable* or olive* or rape* or sunflow* or linseed* or
mono?unsat* or poly?unsat* or saturat* or unsatur*)
lard* in TI,AB
meat* in TI,AB
garlic* in TI,AB
legum* in TI,AB
marg?rine* in TI,AB
butter* in TI,AB
bean* in TI,AB
#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
or #21 or #22
explode “Lipoproteins”/ all subheadings
explode “Triglycerides”/ all subheadings
lipid*
cholesterol*
lipoprotein*
triglyceride*
HDL*
LDL*
#24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#23 and #32
(TG=ANIMAL) not ((TG=HUMAN) and (TG=ANIMAL))
RANDOMIZED-CONTROLLED-TRIAL in PT
CONTROLLED-CLINICAL-TRIAL in PT
RANDOMIZED-CONTROLLED-TRIALS
RANDOM-ALLOCATION
DOUBLE-BLIND-METHOD
SINGLE-BLIND-METHOD
#35 or #36 or #37 or #38 or #39 or #40
#33 not #34
explode “Child”/ all subheadings
explode “Adult”/ all subheadings
#43 and #44
#43 not #45
#41 and #42
#47 not #46
These search strategies were adapted for use on the Cochrane Li-
brary (to 1998 issue 2), EMBASE (Ovid on line to May 1998),
the CVRCT Registry (May 1998), CAB Abstracts (Ovid on-line,
1973 to March 1998) and SIGLE (to January 1999).
Published systematic reviews addressing diet and heart health were
sought as a source of RCTs using similar strategies on MEDLINE
(Silver Platter, 1966-March 1998) and Cochrane (to 1998 issue
1).
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Cochrane ReviewGroups in areas related to this review include the
Diabetes Group (now the proposed Endocrine andMetabolic Dis-
orders Group), Stroke Group, Renal Group, Hypertension Group
and Peripheral Vascular Disease Group. The groups were con-
tacted and asked to search their trial registers for relevant trials.
Bibliographies of all identified systematic reviews, major non-sys-
tematic reviews and included trials were searched for further trials.
Experts in the field were contacted (May 1999) for references to
studies not yet identified by the search process. The 60 experts
were defined as persons who served as author (not necessarily the
primary author) on a trial meeting inclusion criteria for the review,
or the contact author for any relevant systematic review or exten-
sive non-systematic review. All contacted authors of trials were also
asked whether they knew of trials which may have been missed.
Attempts were made to obtain translations of relevant non-En-
glish articles, or contact with the author was established to enable
assessment of eligibility.
Data collection and analysis
DATA COLLECTION
Articles were only rejected on initial screen if the reviewer could
determine from the title and abstract that the article was not a
report of a randomized controlled trial; or the trial did not address
a low or modified fat diet; or the trial was exclusively in children
less than 18 years old, pregnant women or the critically ill; or
the trial was of less than 6 months duration; or the intervention
was multi-factorial. When a title/abstract could not be rejected
with certainty, the full text of the article was obtained for further
evaluation.
The inclusion of studies was assessed independently by two as-
sessors (LH and RLT) and differences between reviewers’ results
resolved by discussion and, when necessary, in consultation with a
third reviewer (RAR). Trials were categorised as “possible” (where
all inclusion criteria appeared to be met or where the ascertain-
ment, or otherwise, of outcome events was uncertain, to be re-
solved by writing to the author) or “excluded”. Attempts were
made to contact all authors of “possible” trials in order to confirm
or ascertain whether inclusion criteria were met.
A data extraction formwas designed for this review. Data concern-
ing participants, interventions and outcomes, trial quality charac-
teristics (Chalmers 1990), data on potential effect modifiers in-
cludingparticipants baseline risk of cardiovascular disease, trial du-
ration, intensity of intervention (dietary advice, diet provided, di-
etary advice plus supplementation, supplementation alone), med-
ications used (particularly lipid lowering medication) and smok-
ing status, numbers of events and total patient years in trial were
extracted. Where provided, data on risk factors for cardiovascular
disease including blood pressure, lipids and weight were collected
Baseline risk of cardiovascular disease was defined as follows: high
risk are participants with existing vascular disease including a his-
tory of myocardial infarction, stroke, peripheral vascular disease,
angina, heart failure or previous coronary artery bypass grafting
or angioplasty; moderate risk are participants with a familial risk,
dyslipidaemia, diabetes mellitus, hypertension, chronic renal fail-
ure; low risk are other participants or mixed population groups.
Original reports of trial results were extracted by two reviewers
(LH and RLT). Differences were resolved by discussion.
DATA SYNTHESIS
Primary measures of interest were the effect of intervention on
1. total and cardiovascular mortality
2. combined cardiovascular events (including cardiovascular
deaths, non-fatal myocardial infarction, stroke, angina, heart fail-
ure, peripheral vascular disease, angioplasty and coronary artery
bypass grafting)
3. quality of life measures.
Pre-specified analyses included:
Meta-analysis of data on the following outcomes:
· total mortality
· cardiovascular mortality
· combined cardiovascular events
Each of these was ranked according to the percentage energy from
fat in the control group, starting high.
Meta-analysis, sub grouping by
· trials with mean follow-up time over 2 years
· initial level of risk (low, medium, high)
· mode of intervention (advice, supplementation or provision of
diet)
for total mortality and total cardiovascular events as outcomes.
Meta-regression on total mortality outcome and total cardiovas-
cular events by change in
· difference in total fat as a percentage of energy between the
intervention and control groups
· difference in total serum cholesterol between the intervention
and control groups
The data were in the form of rates. Treatment effect was mea-
sured as a rate ratio and meta-analysis performed as a weighted
average of (ln) rate ratios (as described by Hasselblad 1995). For
trials with a zero in one arm of the data a small number (0.5)
was added to the number of events in both groups. Trials where it
was known that there were no events in either intervention group
were included in the review for completeness, but could not be
included in the meta-analysis. Where trials ran one control group
and more than one included intervention group, data from each
intervention group were used and the events and patient-years in
the control group were divided into equal shares. This resulted in
fractional numbers of events in some cases. It was planned that if
trials randomized by cluster were identified the patient numbers
would be reduced to an “effective sample size” (as described by
Hauck 1991), however none were identified that were both in-
cluded and had cardiovascular events or deaths.
Meta-analysis was performed (by JPTH) using random effects
methodology (DerSimonian 1986) within S-PLUS (Higgins
1999). Random effects meta-regression (Berkley 1995) was per-
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formed using the STATA command metareg (Sharp 1998). Fun-
nel plots were drawn to examine the possibility of publication bias
(Egger 1997).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of ongoing
studies.
Twenty seven studies are included in the review and are described
in the table ’characteristics of included studies’. Fourmore trials are
ongoing, described in the table ’characteristics of ongoing studies’.
219 trials have been excluded, and the reasons for these exclusions
are described in the list of references. After the trial author and year
the number in brackets refers to the reason for exclusion. These
are as follows:
1: the trial was not randomized, orwas not adequately randomized,
or there were less than six groups for cluster randomization,
2: therewas no control group, or nousual or control diet or placebo
group for the dietary intervention arm of the trial,
3: the stated aim of the intervention was not reduction or modifi-
cation of dietary fat or cholesterol intake (increasing omega-3 fats
was excluded),
4: the intervention was multi factorial and the effects of the dietary
intervention could not be separated from those of other types of
intervention,
5: the intervention group were not adult humans, or were acutely
ill or were pregnant,
6: the intervention (diet provided or supplementation) did not
continue for at least 6months (or 26weeks or 180 days) or (dietary
advice) the participants were not followed up for at least 6months,
7: neither mortality nor cardiovascular morbidity data were avail-
able (this was only decided definitely after contact with at least one
author), trials where it was known that no events occurred were
included.
A few studies remain where contact with the authors has not yet
been established, or contact with the authors has not yet ascer-
tained whether it is known that events occurred. These studies
have been included on all criteria above except for number 7. They
are at the end of the list of Studies awaiting assessment, labelled
’Z pending’, other studies in this list have not yet been assessed
for inclusion in duplicate.
The 27 included trials comprise 40 distinct intervention arms.
Papers describing these trials range in publication date from 1964
to 1998, and were conducted in North America (11), Europe (15)
and Australia (1). Seven of the trials include only people at high
risk of cardiovascular disease, six at moderate risk, 14 at low risk.
All of the high risk trials were men only, women were included
in five low risk trials and eleven low or medium risk trials. Thus
most of the included events occurred in men.
Of the 40 intervention arms only 17 provide useable event data,
and only 8 provide data on more than 10 events in total.
Dietary interventions varied from trials which provided themajor-
ity of food for their participants over several years of study (2), tri-
als which advised diets with dietary fat restriction or modification
(17), and those which provided a combination of dietary advice
and supplementation (8). The goals of the dietary alteration varied
enormously, aiming for fat levels between 15 and 45 per cent of
dietary energy, either reducing total fat or replacing saturated by
unsaturated fats, sometimes aiming to reduce dietary cholesterol.
Specific advice was sometimes given as to type of carbohydrates
to be used, calorie restrictions, amounts of fibre, amounts of fruit
and vegetables, poultry and fish. Supplements included oil (to be
drunk daily or used in cooking), low ormodified fat foods supplied
by a trial shop, margarines, milk, oily fish, vitamin supplements
and fibrous biscuits.
Of the 40 intervention arms included 15 aimed only to lower
total fat intake (of which two had cardiovascular events), 14 aimed
to modify the type of fat eaten (of which ten had cardiovascular
events), nine arms aimed to both lower total fat and modify the
type of fat eaten (of which five had cardiovascular events), one
aimed only to lower dietary cholesterol intake and the final arm
did not state what its dietary aims were (neither of these two had
events).
Of these trials only nine stated that an intended outcome was to
assess mortality or cardiovascular morbidity of some sort. A fur-
ther 13 intended tomonitor lipid or cardiovascular risk factor out-
comes, and the remainder aimed to assess the following outcomes:
bile acid kinetics, feasibility of dietary intervention, occurrence of
retinopathy or skin cancer and recurrence of neoplastic polyps.
Risk of bias in included studies
All trials included were randomized controlled trials. Those with
detected pseudo random allocation (for example where partici-
pants are randomized according to birth date or alphabetically
from their name) were excluded. It is often difficult to assess
whether the allocation group was concealed from the person de-
ciding on eligibility for the trial, but the actual phrase describ-
ing the process of randomization (from published or unpublished
material) is included in the table on characteristics of included
studies. Allocation concealment was not duplicate data extracted,
but for most studies it would probably be ’unclear’.
Physician blinding (for the purpose of diagnosing outcomes)
makes little difference where total mortality is the outcome, but
is important for all other outcomes. Blinding was adequate for 11
trials, inadequate for three and unclear for 13.
Participant blinding is difficult in dietary trials, but possible where
all or some food is provided by the trial. Participant blinding was
adequate for three trials, inadequate for 22 and unclear for two.
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A systematic difference in care between the control and interven-
tion groups (such that any differences in the results of the trial
might result from these differences and not the dietary interven-
tion) was not present in 17 trials, “minor” in eight, present in one
and unclear in one. There was never any indication that there was
a difference in the use of medications between the control and
intervention groups (which could potentially have swamped out
any differential effects of diet).
Effects of interventions
Overall 18,196 people were included in the 27 included trials
(8647 in the control groups, 9549 in the intervention groups),
over 30,901 person-years of observation (15096 control, 15806
intervention). Details of the extracted rate data are seen in Table
1, ’Outcome data from included trials’. 1430 total deaths were
documented (520 in high risk groups), 812 cardiovascular deaths
(393 inhigh risk groups) and1216 combined cardiovascular events
(721 in high risk groups).
Of the 27 trials, 13 were documented as having had no mortality
and/or no cardiovascular events. Three trials had known events,
but it has not been possible to ascertain the randomization group
for these people (Oxford Retinopathy 34 deaths, BDIT Pilot
Studies three deaths, Low Fat in Breast CA at least two deaths). All
of the seven trials which included high risk participants (DART,
London Corn/Olive, London Low Fat, MRC Soya, Oslo Diet-
Heart, STARS, Sydney Diet-Heart) did have documented events,
as did four trials in low risk groups (Minnesota Coronary,National
Diet-Heart, Veterans Admin and Veterans Skin CA).
Data on quality of life outcomes were only found for one trial,
and so were not extracted.
Funnel Plot
A funnel plot was drawn to indicate whether publication bias
was likely (using total mortality data). Only trials with events
can be plotted by this method. The funnel plot appears fairly
symmetrical suggesting an absence of serious bias. The funnel plot
can be viewed on the web site of the Cochrane Heart Group (http:
//www.epi.bris.ac.uk/cochrane/heart.htm).
Inter-rater agreement
The kappa statistic for inter-rater agreement on including or ex-
cluding potential trials was 0.61.
Meta-analyses
The numerical results of all meta-analyses performed are shown in
Table 2, ’Results of random effects meta-analyses and sub group-
ing’. (As meta-analysis was performed using rate data it is not pos-
sible to display the pictorial results of these calculations within
the Cochrane Library. They can be viewed on the web site of
the Cochrane Heart Group (http://www.epi.bris.ac.uk/cochrane/
heart.htm).
Meta-analysis suggests that, over 30,901 person-years of observa-
tion, for people of varying risk of cardiovascular disease, there is
no significant effect of alteration in quantity and/or quality of di-
etary fat on total mortality. Our best estimate of the rate ratio is
0.98 (95% CI 0.86 to 1.12). A rate ratio of 1.0 would indicate no
effect, less than 1.0 suggests benefit from the intervention (in this
case dietary fat modification), and greater than 1.0 suggests harm
from the intervention.
The effect on cardiovascular mortality suggests a trend towards
protection by modification of dietary fat, but this is not statisti-
cally significant, rate ratio 0.91 (95% CI 0.77 to 1.07). The trend
towards protection is strengthened when the effect on combined
cardiovascular events is considered, this is significant, with a rate
ratio of 0.84 (95% CI 0.719 to 0.986).
Meta-analysis was repeated excluding the results of the Oslo
Diet-Heart trial which provided oily fish to participants in the low
dietary fat arm. As oily fish appears to reducemortality and cardio-
vascular events in high risk people (Hooper 1999), it may be the
oily fish rather than the low fat diet providing the observed effect.
Removing the Oslo Diet-Heart trial attenuated the rate ratios for
all three main outcomes (total mortality 1.02, 95% CI 0.91, 1.14;
cardiovascular mortality 0.94, 95% CI 0.79, 1.11; combined car-
diovascular events 0.86, 95% CI 0.72, 1.03). The rate ratio for
combined cardiovascular events was no longer significant.
Each of the intervention arms in each of the trials was ranked
according to the percentage energy from fat in the control group,
starting high, for each of the three preceding meta-analyses. There
was no obvious trend (to the eye) as a result of this ordering.
Sub grouping
Within the above meta-analyses there was no significant statistical
heterogeneity, however the trials performed varying interventions
on groups at very different cardiovascular risk so that some clinical
heterogeneity was certainly present. For this reason random effects
meta-analysis was performed (Mosteller 1992), and the effects of
this clinical heterogeneity was explored by sub-group analysis and
meta-regression (Thompson 1991).
Sub grouping was by mean follow-up time in trial, by initial level
of cardiovascular risk and by the style of dietary intervention.
These were each explored for two outcomes, total mortality and
combined cardiovascular events.
Exploring heterogeneity through sub grouping for length of time
in trial, for level of cardiovascular risk and for style of intervention
still offered no significant effects on mortality, although there was
a suggestion of increased protection during trials of more than 2
years.
Trials where participants were involved for more than 2 years on
average did show significant reductions in the rate of combined
cardiovascular events (the pooled estimate of the rate ratio was
0.76, 95% CI 0.65 to 0.90, compared to a rate ratio of 0.84 for
all trials combined). The reduction in events remained statisti-
cally significant when the results of the Oslo Diet-Heart trial were
omitted from the analysis.
Trials of those at high initial cardiovascular risk (pooled estimate
of the rate ratio was 0.84, 95% CI 0.70 to 0.99) suggested very
similar levels of protection from combined cardiovascular events
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as trials of those at low cardiovascular risk (the pooled estimate of
the rate ratio was 0.82, 95% CI 0.56 to 1.20, compared to a rate
ratio of 0.84 for all trials combined) despite the estimate for those
at low cardiovascular risk not being statistically significant. The
style of dietary modification (dietary advice, supplementation or
diet provided) did not influence rate ratios.
Meta-regression
Meta-regression was used to explore the effects of changing the
percentage of energy from fat and of altering serum cholesterol
levels on two outcomes, total mortality and combined cardiovas-
cular events.
For the two calculations involving percentage of energy from to-
tal fat, the information extracted from each trial was the percent-
age of energy from fat achieved in the intervention group, minus
the percentage of energy from fat achieved in the control group
(so that where the fat intake is lower in the intervention group,
the number used is negative). Similarly, for the two calculations
involving serum total cholesterol, the information extracted was
the serum total cholesterol (in mmol/litre) achieved in the inter-
vention group, minus the serum total cholesterol achieved in the
control group (so that where the serum cholesterol is lower in the
intervention group, the number used is negative).
The numerical results of all the meta-regressions performed are
shown in Table 3, ’Results of random effects meta-regression’,
the visual representations can be viewed on the web site of
the Cochrane Heart Group (http://www.epi.bris.ac.uk/cochrane/
heart.htm). Rate ratios for total mortality and total cardiovascular
events dropped as the percentage energy from fat fell, and as total
serum cholesterol levels fell. However, none of the trends were
statistically significant. This may be in part due to the large dif-
ferences in interventions between the trials. It is also the case that
the larger trials did not reduce dietary fat extensively, so that these
trials are clustered together leaving only smaller trials to suggest
the actual slope of the relationship, making a statistically signifi-
cant correlation less likely.
D I S C U S S I O N
This review suggests that dietary fat reduction ormodificationmay
be protective of cardiovascular events, but this is still not clear.
The National Diet-Heart study (published in 1968) was carried
out as a pilot study for a large scale test of the efficacy of dietary fat
modification in the general (male) population on cardiovascular
morbidity and mortality. The definitive trial was never begun due
to cost considerations. It is unlikely now that this failure to conduct
the definitive trial will ever be rectified.
Length of follow-up
If dietary fat modification has some immediate effect on mortal-
ity or cardiovascular morbidity (for example, by altering clotting)
then number of years observation on each individual may not be
very important, and effect could be seen in a trial with many par-
ticipants followed over a short time, as well as in a trial with fewer
participants followed over a long time. If their main effect takes
some time to manifest itself (for example by slowly altering degree
or type of an atherosclerotic plaque) then the effect may be seen
after a “lag” period. In this case the trial with many participants
followed over a short time may show no effect at all, but the trial
with fewer participants followed over a longer time period will be
more likely to show an effect, even if the total number of person-
years of observation is the same.
In the 4S trial (4S 1994) 4444 participants were followed for
roughly 19,339 person-years of observation, a mean of 4.35 years
each. The Kaplan-Meier curve for all-cause mortality for the 4S
trial only shows a clear separation between the two randomisation
groups at roughly 2 years. For this reason trials within the system-
atic review were grouped into those with a mean follow-up of two
years or less, and those with mean follow-up of more than two
years.
Pooled results of dietary fat trials indicate that reduction or mod-
ification of dietary fat intake does significantly reduce the inci-
dence of combined cardiovascular events. The effect is consistent
with a benefit as large as a 28 per cent reduction in events, with a
best estimate of 16 per cent reduction in events. This effect is seen
almost exclusively in those who continue to modify their diet over
at least two years. The trials with follow-up times from 6 months
to 2 years may be diluting the effect of the trials with more than
two years follow-up in the overall meta-analysis, but data on time
to event were not available (the rate ratio for combined cardio-
vascular events is 0.84 overall, 0.96 in trials with mean follow-up
of two years or less, 0.76 in trials with a mean follow-up of more
than two years).
Total mortality was examined as there is no likelihood of ascer-
tainment or diagnostic bias which may occur with cause-specific
event outcomes. The data follow a similar trend, with no effect in
the shorter trials and a suggestion of benefit in the trials of more
than two years, but here the trend is not significant (the rate ratio
for total mortality is 0.98 overall, 1.04 in trials with mean follow-
up of two years or less, 0.93 in trials with a mean follow-up of
more than two years).
This suggests that the effects of dietary fat modification will take
time to manifest themselves, and there is little evidence of imme-
diate effects on factors such as thrombosis. The main effects of
dietary fat reduction and modification are likely to be on the scale
and type of atherosclerotic plaque, but other mechanisms may be
operating.
Degree of lipid lowering
Following the 4S trial it is well established that lipid lowering
through use of statins does have a protective effect on people at
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high risk of cardiovascular disease. This and more recent statin
trials have shown a highly significant 25 per cent fall in coronary
heart disease mortality (Ebrahim 1998).
If the protective effect of statins relates to their lipid lowering effect
then the extent of lipid lowering within the dietary trials might be
important. A summary of the lipid lowering effects of the major
intervention trials of statins (Ebrahim 1998) suggests an average
reduction of total serum cholesterol of over 20 per cent. Within
the set of dietary trials used for this review the mean individual
initial total serum cholesterol level was 5.8 mmol/litre, and the
average change over the trial was a fall of 0.64 mmol/litre (11.1%).
This is a much smaller effect on serum cholesterol than that of the
statins, and is similar to the fall provided by bibrates which do not
appear to reduce clinical events (Ebrahim 1998).
Rather surprisingly much of the total cholesterol reduction in the
dietary trials comes from a low risk trial, the Minnesota Coronary
trial, as modified institutional food was provided to a vast number
of low risk people over only one year on average, resulting in a large
reduction in total cholesterol, but with little change in cardiovas-
cular events and a slight increase in mortality. If the Minnesota
Coronary trial is excluded the initial total serum cholesterol level
within the dietary trials is 6.46 mmol/litre and the mean change
in total cholesterol between the control and intervention groups is
a fall of 0.47 mmol/litre (7.3%) in the intervention groups, only a
third of the total serum cholesterol fall expected with statin ther-
apy.
This relatively small degree of lipid lowering may be a reason that
no significant effect of dietary fat intervention was seen on total or
cardiovascular mortality in the short term. The larger number of
total cardiovascular events thanof deaths provides greater statistical
power. There was a suggestion from the meta-regression that a
greater degree of reduction of total serum cholesterol resulted in a
greater reduction in events.
Participants level of risk
As the rate of events will be higher in high risk groups, it should be
possible to see the effect of an intervention more rapidly in a high
risk group of participants (Davey Smith 1993). There have been
suggestions that randomized controlled trials are unsuitable for
assessing the effectiveness of interventions with very modest levels
of effect in low risk populations, because of the huge numbers
of person-years of observation needed to gain sufficient statistical
power to avoid Type II errors (Ebrahim 1997). It may be very
difficult to disprove effectiveness even when such interventions are
clinically useless.
In this review a similar level of risk reduction of combined cardio-
vascular events is seen in both high and low risk groups, but this
effect only reaches statistical significance in the high risk partici-
pants. This is likely to be due to a relative lack of endpoints in the
lower risk population.
When endpoints such as mortality are used the situation becomes
more difficult as in low risk groups the proportion of deaths which
are unrelated to cardiovascular disease (and unlikely to be influ-
enced by dietary fat changes) rises, again diluting any differences in
the numbers of deaths between intervention and control groups.
It is more likely that significant changes in cardiovascular deaths
will be seen than in total mortality. The trend is certainly in this
direction (pooled rate ratio for total mortality 0.98, for cardiovas-
cular mortality 0.91). Our best estimate is that dietary fat reduc-
tion and modification result in a reduction of 9 per cent in deaths
due to cardiovascular disease, and a reduction of 2 per cent in total
deaths, but the confidence intervals are wide.
The high risk participants in the dietary fat trials all show evidence
of cardiovascular disease. Under current guidelines most high risk
participants with raised lipid levels should be on statin therapy
(Wood 1998). This raises the question of whether there is any
additional advantage of adherence to a low or modified fat diet
in addition to statin therapy. Little evidence exists at present to
answer this question. However, in all parts of the world where drug
budgets are restricted and use of statins remains rationed even for
those at high risk the use of low or modified fat diets would appear
to be a cost-effective option leading to considerable reductions
in cardiovascular events (and so in health budgets) in only a few
years.
The low risk participants are unlikely to be on statin therapy under
current guidelines. The suggestionof protection of this group from
cardiovascular events, with a reduction of roughly 18 per cent
of events, by dietary fat modification (even though this does not
reach statistical significance, but taking into account the lack of
power) would appear to merit continued public health action.
Low fat or modified fat diets
An individuals dietary intake is a complex mixture of foods, each
of which is a complex mixture of nutrients. Altering one dietary
component leads to unintentional alterations inmany others, each
of whichmay have positive or negative effects on several risk factors
and, eventually, health.
The fat interventions included in this review are low fat diets
(where total fat is reduced, and energy is usually replaced by in-
creasing carbohydrate intake), modified fat diets (where a propor-
tion of saturated fat is replaced by unsaturated fats, and total fat
intakes do not alter) and combinations of the two (with some fat
reduction and some replacement with unsaturates). Whilst these
diets have similar effects on total serum cholesterol levels it may
be that their effects on cardiovascular disease incidence and mor-
tality are different. For example, low fat, high carbohydrate diets
are likely to result in higher triglyceride and lower HDL choles-
terol levels than a diet where saturated fats are wholly replaced by
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unsaturated fats (Mensink 1992). As only two low fat trial arms
with events are included in the meta-analyses, it would not be
possible to separate out the effects of the various types of dietary
fat changes on mortality and morbidity within this review. But if
we aim to achieve best cardiovascular protection (rather than the
best cholesterol reduction) we must be clear about exactly what
dietary advice is advocated. Further large scale, long term trials
with disease end points would be needed to clarify this, but are
unlikely to be mounted given the feasibility and cost consider-
ations. However, results of large scale, long term ongoing trials
like the Polyp Prevention trial (due to report soon), WINS and
Canadian DBCP may help to clarify the effect of low fat diets on
total mortality, and also on cardiovascular events in those at low
risk of cardiovascular disease.
Improved interventions
Interventions on dietary fat need to result in useful levels of choles-
terol reduction and these must be sustained for at least two years
to have an impact on levels of cardiovascular events. Systematic
reviews of the effect of diet on serum cholesterol levels have sug-
gested that levels of serum cholesterol reduction are much lower
in free-living low risk groups than in high risk groups (Ebrahim
1998). We might expect reductions in serum cholesterol of only 3
to 5 per cent even with quite intensive interventions in the general
population (Brunner 1997; Tang 1998). Interventions in high risk
populations appear to reduce serum cholesterol levels by about ten
per cent. This difference is likely to be because of lower levels of
motivation and long term dietary compliance in those who have
not experienced cardiovascular disease themselves (Tang 1998).
Effective interventions tend to focus specifically on dietary (rather
than multiple lifestyle) changes, to incorporate behavioural the-
ories and goals, use active involvement and specific behaviour
change strategies, personalise the intervention, provide feedback
and multiple contacts and build support through contact with
family, colleagues or local leaders. Changing the environment by
increasing availability of healthy choices, using simple signs to
identify them and/or manipulating food composition without
publicising the fact may also be productive (Roe 1997).
There is also confusion about whether low fat or modified fat
changes are most effective. It is important that individuals and
populations are receiving clear, evidence-based advice about the
types of dietary fat changes which are most effective in reducing
cardiovascular risk, as well as ways to achieve those changes. Fur-
ther research comparing low fat and modified fat changes on car-
diovascular disease risk factors would be feasible and helpful.
Most of the events analysed in this review come from male partic-
ipants. It may be that the effect of dietary fats on women’s risk of
cardiovascular events is distinct from those of men.
Other systematic review results
This review aimed to find all relevant dietary intervention trials
which reduced or modified dietary fat intake, followed its partici-
pants for at least six months and collected mortality or morbidity
data, even when the individual trials were not powered to come to
any conclusions about mortality or morbidity.
Results of this systematic review are similar to those of a less rig-
orous systematic review by Ebrahim and Davey Smith (Ebrahim
1996). They examined ten unifactorial dietary trial arms which
resulted in serum cholesterol lowering. They found nonsignificant
reductions in both total mortality (odds ratio 0.96, 95% CI 0.85
to 1.08) and coronary heart disease mortality (odds ratio 0.98,
95% CI 0.83 to 1.15).
Results of these systematic reviews conflict with a previous sys-
tematic review by Truswell on dietary interventions and mortal-
ity or morbidity outcomes (Truswell 1994) which found that di-
etary interventions significantly reduced total mortality (pooled
odds ratio 0.94). However his inclusion criteria were very differ-
ent, including interventions which did not aim to alter dietary fat
or serum cholesterol, multifactorial interventions and a non-ran-
domized trial (the Finnish Mental Hospital trial, Miettinen 1972
(1)), and excluding at least one relevant intervention arm (the olive
oil arm of the London Corn/Olive trial).
This review is suggestive that dietary fat alteration is protective
against combined cardiovascular events. No significant effect on
total mortality is seen, probably because the analysis is under pow-
ered (with only half of the high risk observation years of the 4S
study, less than half of its total cholesterol lowering effect and few
participants involved for long enough to see any effect), but the
suggestion is a reduction in total mortality in those following a
reduced and/or modified fat diet for at least two years. However,
it may be that there is no effect of dietary fat reduction and/or
modification on total mortality.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Dietary change to reduce ormodify dietary fat intake appears to re-
duce the incidence of combined cardiovascular events. This trend
is statistically significant for all trials, but when a trial which also
increased omega-3 fat intake in the intervention group is excluded
the results are no longer statistically significant. The protective
effect is seen almost exclusively in those who continue to modify
their diet over at least two years. The extent of this protection
appears similar in both high and low risk populations, although
the relationship does not achieve statistical significance in low risk
participants. Dietary advice to those at high risk of cardiovascu-
lar disease (particularly where statins may not be available), and
probably also to lower risk population groups, should continue to
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include dietary fat modification and it should be stressed that this
is a permanent pattern of eating.
There is a suggestion that dietary fat modification has protective
effects on total mortality and on cardiovascular mortality when
the dietary modification is followed for at least two years, however
this trend is not statistically significant. It may be that not enough
people were involved in long term trials to show the protective
effect of a change in dietary fat, or it may be that there is no such
effect.
Implications for research
Thefinancial implications (costs and savings) of appropriate advice
and legislation to modify fat intake in those at various levels of
cardiovascular risk should be assessed and reflected inhealth policy.
It is not clear whether there is additional benefit of modifying
dietary fat in those at high risk of cardiovascular disease who are on
statins to reduce their cholesterol levels.Most of the trials of statins
required participants in both control and intervention groups to
receive dietary fat advice. Further research to examine the need for
maintenance of dietary fat modification whilst on statins would
only be feasible using serum cholesterol changes, but the issue is
not of major importance.
Whilst interventions to alter dietary fat intake in individuals at
high cardiovascular risk have been fairly successful, such health
promotion initiatives in the general population have been less suc-
cessful. Further work is needed to help high and low risk individ-
uals to make effective changes to dietary fat and to maintain these
changes over their lifetimes. Research into the effects of improved
labelling, pricing initiatives and improved availability of health-
ier foods, linking food production and processing into the health
agenda may yield huge advances in this area.
It is not clear whether a low fat diet, a modified fat diet, or a
combination of both is most protective of cardiovascular events.
Results from ongoing trials which are assessing the effects of low
fat diets on certain cancers may help to clarify the different effects
of low and modified fat diets on mortality.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
BDIT Pilot Studies
Methods ”randomly allocated“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: unclear
Participants women with mamographic dysplasia (Canada)
CVD risk: low
control: n= 147
intervention: n= 148
mean years in trial: 7.2
% male: 0
age: mean 45 (all >30)
Interventions control aims: healthy diet advice, no alteration in dietary fat advised
intervention aims: total fat 15%E, replace fat by complex CHO
style: diet advice
Outcomes stated trial outcomes: dietary fat, serum cholesterol
data available on total mortality? yes, but in which intervention group is unclear
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
DART
Methods ”randomised“, physician blinding: unclear
participant blinding: unclear
systematic difference in care: no
Participants men recovering from an MI (UK)
risk: high
CVD control: n= 1015
intervention: n=1018
mean years in trial: 1.89
% male: 100
age: mean 57 (all <70)
Interventions control aims: no dietary advice on fat
intervention aims: reduce fat intake to 30%E, increase P/S to 1.0
style: diet advice
Outcomes stated trial outcomes: mortality, reinfarctions
data available on total mortality? yes
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DART (Continued)
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths (including stroke deaths) plus non-fatal
MI
Notes
Diet & Gallstones
Methods ”randomly allocated“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants people with radiolucent gallstones taking UDCA (USA)
CVD risk: low
control: n= 17
intervention: n= 19
mean years in trial: 0.59
% male: 47
age: mean 53
Interventions control aims: dietary advice for total fat 38-42%E, dietary chol 500mg/day
intervention aims: limit dietary chol to 250mg/day
style: diet advice
Outcomes stated trial outcomes: bile acid kinetics
data available on total mortality? yes
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
German Fat Reduced
Methods ”participants assigned to a random number, later numbers sorted & assigned“, physician blinding: unclear
participant blinding: unclear
systematic difference in care: no
Participants women with BMI 24-29 (Germany)
CVD risk: low
control: n= 35
intervention: n= 35
mean years in trial: 0.73
% male: 0
age: mean 47 (all 40-60)
Interventions control aims: advice to buy foods from trial shop, usual fat foods supplied
intervention aims: to buy foods from trial shop, low fat foods supplied
style: dietary advice & supplement (shop foods)
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German Fat Reduced (Continued)
Outcomes stated trial outcomes: weight
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, stroke
Notes
Glasgow Diet in HT
Methods ”stratified by antihypertensive treatment, randomly allocated“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: minor
Participants hypertensives with cholesterol >6.5mmol/L (UK)
CVD risk: moderate
control: n= 72
intervention: n= 72
mean years in trial:0.46
% male: 49
age: mean 56
Interventions control aims: no dietary advice
intervention aims: reduce serum cholesterol
style: diet advice
Outcomes stated trial outcomes: blood pressure, weight, lipids
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths
Notes
Glasgow Weight Loss
Methods ”medical officer drew coloured straws from a box“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants healthy women, BMI >25 (UK)
CVD risk: low
control: n= 53
intervention: n= 57
mean years in trial: 0.43
% male: 0
age: mean 51
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Glasgow Weight Loss (Continued)
Interventions control aims: advice - total fat 35%E, CHO 34.5%E, 1200kcal per day
intervention aims: total fat 20%E, CHO 58%E, 1200kcal/day
style: diet advice
Outcomes stated trial outcomes: weight loss and cardiovascular risk factors
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, non fatal MI, stroke
Notes
Kentucky Low Fat
Methods ”matched on age, gender & cholesterol level, randomly assigned to intervention group using systematic random
procedure“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: minor
Participants moderately hypercholesterolaemic, non-obese caucasian men and women aged 30-50 years (USA)
CVD risk: moderate
control: n= 62
intervention: n= 115
mean years in trial: 0.91
% male: 60
age: mean 41 (all 30-50)
Interventions control aims: no diet intervention
intervention aims: 25%E from fats, 20%E from protein, 55%E from CHO, <200mg chol /day (differing amounts
of fibre)
style: diet advice
Outcomes stated trial outcomes: diet composition, lipids
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, fatal and non-fatal MI, stroke
Notes
Kuopio Fat Modified
Methods ”randomisation stratified for men and women, singles and couples, random number tables“, physician blinding:
inadequate
participant blinding: inadequate
systematic difference in care: no
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Kuopio Fat Modified (Continued)
Participants free-living people aged 30-60 with serum total cholesterol levels 6.5-8.0mmol/L (Finland)
CVD risk: moderate
control: n= 37
intervention: n= 41/40/41
mean years in trial: 0.5
% male: 46
age: mean 46 (all 30-60)
Interventions 3 intervention groups
control aims: advised total fat 38%E, SFA <18%E, MUFA 15%E, PUFA <5%E, rapeseed oil, butter and semi-
skimmed milk provided
intervention aims: AHA (low fat, mono) - total fat 30%E (28-30%E, 38%E), SFA <10%E (<14%E, <14%E),
MUFA 10%E (10%E, 18%E), PUFA 10%E (4%E, <6%E), sunflower oil (butter, rapeseed oil), sunflower (rapeseed,
rapeseed) spread and skimmed milk (all 3 groups) provided
style: dietary advice & supplement (food)
Outcomes stated trial outcomes: lipids and blood pressure
data available on total mortality? yes
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
Linoleic Enrichment
Methods ”stratified according to gender, randomised in blocks of 6 using opaque sealed envelopes“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants type I diabetics with elevated urinary albumin (Netherlands)
risk: moderate
control: n= 20
intervention: n= 18
mean years in trial: 1.95
% male: 78
age: mean 43 (all 21-65)
Interventions control aims: usual diet (asked not to alter fat or protein intake)
intervention aims: replace SFA by linoleic acid to achieve P/S of 1.0, total fat and protein intake to remain unchanged
style: diet advice
Outcomes stated trial outcomes: albuminuria and serum lipoproteins
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, stroke
Notes
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London Corn/Olive
Methods ”sealed envelopes“, physician blinding: inadequate
participant blinding: inadequate
systematic difference in care: no
Participants people with angina or following MI (UK)
risk: high
control: n= 26
intervention: n= 28, 26
mean years in trial: 1.53
% male: (100?)
age: mean 55 (all <70)
Interventions 2 intervention groups
control aims: usual diet
intervention aims: restrict dietary fat, plus 80g/day corn (olive) oil provided
style: diet advice & supplement (oil)
Outcomes stated trial outcomes: cardiac events
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, angina, stroke
Notes
London Low Fat
Methods ”allocated at random to one of two groups at each hospital“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants men who have recently recovered from their first MI (UK)
CVD risk: high
control: n= 129
intervention: n= 123
mean years in trial: 3.0
% male: 100
age: (all <65)
Interventions control aims: usual diet, overweight subjects given weight reduction advice (mainly CHO reduction)
intervention aims: reduce fat intake to 40g daily, overweight subjects given weight reducing advice
style: diet advice
Outcomes stated trial outcomes: reinfarction, death
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths plus non-fatal MI
Notes
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Low Fat in Breast CA
Methods ”stratification by age, randomisation with block size of 2“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: minor
Participants women at high risk of breast cancer (USA)
CVD risk: low
control: n= 96
intervention: n= 98
mean years in trial: 1.7
% male: 0
age: mean 46 (all 18-67)
Interventions control aims: asked to maintain usual diet
intervention aims: total fat 15%E
style: diet advice
Outcomes stated trial outcomes: feasibility of intervention
data available on total mortality? yes, but unclear as to which intervention group they come from
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
Mastopathy Diet
Methods ”randomly allocated“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: minor
Participants women with severe cyclical mastopathy for at least 5 years (Canada)
CVD risk: low
control: n= 10
intervention: n= 11
mean years in trial: 0.45
% male: 0
age: mean 38
Interventions control aims: given principles of healthy diet, not counselled to alter fat content
intervention aims: total fat 15%E, CHO 65%E
style: diet advice
Outcomes stated trial outcomes: mastopathy symptoms, plasma hormone and lipids
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: none
Notes
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Minnesota Coronary
Methods ”stratified randomisation“, physician blinding: adequate
participant blinding: adequate
systematic difference in care: no
Participants institutionalised men and women living in a mental hospital (USA)
CVD risk: low
control: n= 4516
intervention: n= 4516
mean years in trial: 1.0
% male: 49
age: ranges from <30 to >70
Interventions control aims: usual institutional diet provided
intervention aims: total fat 45%E, PUFA 18-20%E, P/S 2.5, less than 150mg/day dietary chol
style: diet provided
Outcomes stated trial outcomes: MI, mortality, sudden deaths
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: total MI plus sudden death plus stroke
Notes
MRC Soya
Methods ”allocated at random“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: no
Participants free-living men who have survived a first MI (UK)
CVD risk: high
control: n= 194
intervention: n= 199
mean years in trial: 3.7
% male: 100
age: (all <60)
Interventions control aims: usual diet
intervention aims: reduce dietary fat to 35g fat per day, add 84g soya oil per day
style: diet advice & supplement (soya oil)
Outcomes stated trial outcomes: MI or sudden death
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths and fatal or non-fatal MI
Notes
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MSFAT
Methods ”stratified randomisation (according to sex, age, QI index and eating behaviour) by co-ordinating centre“, physician
blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants healthy people aged 20-55 (Netherlands)
CVD risk: low
control: n= 120
intervention: n= 120
mean years in trial: 0.48
% male: 50
age: 35.8 (all 20-55)
Interventions control aims: advised to use products from trial shop ad lib. (usual fat products provided)
intervention aims: advised to use products from trial shop ad lib. (low fat products provided)
style: dietary advice & supplements (food provided by trial shop)
Outcomes stated trial outcomes: weight, vitamin and fatty acid intake, anti-oxidative capacity
data available on total mortality? yes
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
National Diet-Heart
Methods ”central stratified randomisation“, physician blinding: adequate
participant blinding: adequate
systematic difference in care: no
Participants men living in an institution USA)
CVD risk: low
control: n= 781
intervention: n= 1475
mean years in trial: varies from 0.58 to 0.96 in different trial arms
% male: 100
age: (all 45-54)
Interventions Faribault First Trial (3 intervention arms)
control aims: diet provided aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4
intervention aims: B (C, E) total fat 30%E (40%E, 40%E), SFA <9%E (<9%E, not stated), dietary chol 350-450mg/
d (350-450mg/d, not stated), PUFA 15%E (18-20%E, not stated), P/S 1.5 (2.0, 4.4)
style: diet provided
Open, First Trial (3 intervention arms)
control aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4
intervention aims: B (C,X) total fat 30%E (40%E, 30%E), SFA <9%E (<9%E, <9%E), dietary chol 350-450mg/d
(350-450mg/d, 350-450mg/d), PUFA 15%E (18-20%E, 15%E), P/S 1.5 (2.0, 1.5)
style: B, C - diet advice (reduce dietary saturated fat and cholesterol) & supplementation (purchase fat modified
foods from trial shop), X - diet advice
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National Diet-Heart (Continued)
Open, Second Trial (4 intervention arms: BC, F, G, X))
control aims: BC, F, G - total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4, X - advice to continue
usual diet
intervention aims: BC (F, G, X) total fat 30-40%E (40%E, 40%E, 30%E), SFA reduced (no data, no data, <9%),
dietary chol 350-450mg/d (ditto all 3 other groups), increased PUFA (increased, no data, 15%E), P/S 1.5-2.0 (3.0,
10.0, 1.5)
style: BC, F, G - dietary advice & supplementation as above, X - diet advice
Outcomes stated trial outcomes: lipid levels and dietary assesement
data available on total mortality? no
cardiovascular mortality? yes
events available for combined cardiovascular events: fatal and non-fatal MI, peripheral vascular events
Notes
Oslo Diet-Heart
Methods ”table of random numbers used“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: no
Participants men with previous MI (Norway)
CVD risk: high
control: n= 206
intervention: n= 206
mean years in trial: 4.3
% male: 100
age: mean 56 (all 30-67)
Interventions control aims: no dietary advice but direct questions answered, supplement = 1 vitamin tablet daily
intervention aims: reduce meat & dairy fats, increase fish, vegetables, supplement - 1 vitamin tablet daily, 0.5L soy
bean oil per week (free to 25% of participants), sardines in cod liver oil (free at certain times)
style: diet advice & supplement (food)
Outcomes stated trial outcomes: coronary heart disease morbidity and mortality
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: total MI, sudden death, stroke, angina
Notes
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Oxford Retinopathy
Methods ”random number sequence, provided and allotted by a separate agency“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants newly diagnosed non-insulin dependant diabetics (UK)
CVD risk: moderate
control: n= (125?)
intervention: n= (125?)
mean years in trial: 9.3
% male: 49
age: mean 47.1 (all <65)
Interventions control aims: advice, total fat 40%E, PUFA 12%E, protein 20%E, CHO 40%E (reducing simple sugars), 1500kcal/
day
intervention aims: total fat 26%E, PUFA 16%E, protein 20%E, CHO 54%E (reducing simple sugars), 1500kcal/
day
style: diet advice
Outcomes stated trial outcomes: retinopathy
data available on total mortality? yes, but unable to ascertain from which intervention groups
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
Sollentuna Diet
Methods ”blinded drawing of lots by the study physician“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: minor
Participants men with moderately raised risk factors for cardiovascular disease (Sweden)
CVD risk: moderate
control: n= 40
intervention: n= 40
mean years in trial: 0.5
% male: 100
age: mean 46 (all 35-60)
Interventions control aims: usual diet
intervention aims: total fat 30%E, SFA <10%E, MUFA 10-15%E, PUFA up to 10%E, dietary chol<300mg/day
style: diet advice
Outcomes stated trial outcomes: cardiovascular risk factors (waist line, blood pressure, lipids)
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: total MI, cardiovascular deaths, stroke
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Sollentuna Diet (Continued)
Notes
Stanford Weight
Methods ”assigned at random“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: minor
Participants sedentary, moderately overweight, non-smoking normotensive men (USA)
CVD risk: low
control: n= 44
intervention: n= 45
mean years in trial: 0.9
% male: 100
age: (all 25-49)
Interventions control aims: no dietary advice
intervention aims: total fat <30%E, SFA 10%E, total CHO >55%E, <300mg chol/day, with weight reduction
style: diet advice
Outcomes stated trial outcomes: lipoproteins
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths
Notes
STARS
Methods ”blinded random cards issued centrally by statistician advisor“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: no
Participants men with angina referred for angiography (UK)
CVD risk: high
control: n= 30
intervention: n= 30
mean years in trial: 3.0
% male: 100
age: mean 51 (all <66)
Interventions control aims: no diet intervention
intervention aims: total fat 27%E, SFA 8-10%E, omega-3 and omega-6 polyunsaturates 8%E, increase in plant-
derived soluble fibre, dietary chol 100mg/1000kcal
style: diet advice
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STARS (Continued)
Outcomes stated trial outcomes: angiography, cardiovascular events and procedures
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, angina, stroke, CABG,
angioplasty
Notes
Sydney Diet-Heart
Methods ”random numbers“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: no
Participants men with previous MI (Australia)
CVD risk: high
control: n= 237
intervention: n= 221
mean years in trial: 4.3
% male: 100
age: mean 49 (all 30-59)
Interventions control aims: reduction in energy if overweight, no other specific dietary advice, allowed to use PUFA margarine
instead of butter
intervention aims: SFA 10%E, PUFA 15%E, reduction in energy if overweight, dietary chol <300mg/day
style: diet advice
Outcomes stated trial outcomes: cardiovascular mortality
data available on total mortality? yes
cardiovascular mortality? no
events available for combined cardiovascular events: none
Notes
Toronto Polyp Prev.
Methods ”stratification by physician, gender, age, randomisation by research associate, centrally, using random numbers gen-
erated by computer“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care: minor
Participants people after adenomatous colorectal polypectomy (Canada)
CVD risk: low
control: n= 102
intervention: n= 99
mean years in trial: 2.0
% male: 55
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Toronto Polyp Prev. (Continued)
age: mean 58 (all <85)
Interventions control aims: advice for nutritionally balanced diet (optional low fibre supplement with added calcium and iron)
intervention aims: total fat <20%E, at least 50g fibre daily (optional fibre supplement with added calcium and iron)
style: dietary advice & supplement (food)
Outcomes stated trial outcomes: recurrence of neoplastic polyps
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: none
Notes
Turku Weight
Methods ”randomised according to gender, age and overweight“, physician blinding: unclear
participant blinding: inadequate
systematic difference in care: yes
Participants adults 30-50% overweight (Finland)
CVD risk: low
control: n= 44
intervention: n= 46, 46
mean years in trial: 0.9
% male: 26
age: (all 25-50)
Interventions 2 intervention arms
control aims: usual diet
intervention aims: mixed (vegetarian) - total fat 25-30%E (20-25%E), 1200kcal/day (1200kcal/day), low in sugar,
high in fibre and vegetables, moderate meat, fish & eggs (no meat, fish or eggs)
style: diet advice
Outcomes stated trial outcomes: weight, blood pressure, lipids
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths, total MI, andinga, stroke, heart failure,
angioplasty or CABG
Notes
45Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Veterans Admin
Methods ”table of random numbers used“, physician blinding: adequate
participant blinding: adequate
systematic difference in care: no
Participants men living at the Veterans Administration Centre (USA)
CVD risk: low
control: n= 422
intervention: n= 424
mean years in trial: 3.66
% male: 100
age: mean 65 (all 54-88)
Interventions control aims: provided, total fat 40%E
intervention aims: total fat 40%E, 2/3 of SFA replaced by unsaturated fats, dietary chol reduced
style: diet provided
Outcomes stated trial outcomes: mortality, heart disease
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: sudden death, definite MI, definite stroke, angina, PV events
Notes
Veterans Skin CA
Methods ”list of randomly generated numbers“, physician blinding: adequate
participant blinding: inadequate
systematic difference in care:minor
Participants people with non-melanoma skin cancer (USA)
CVD risk: low
control: n= 67
intervention: n= 66
mean years in trial: 1.9
% male: 60
age: mean 52
Interventions control aims: no dietary advice
intervention aims: total fat 20%E, protein 15%E, CHO 65%E
style: diet advice
Outcomes stated trial outcomes: incidence of actinic keratosis and non-melanoma skin cancer
data available on total mortality? yes
cardiovascular mortality? yes
events available for combined cardiovascular events: cardiovascular deaths
Notes
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Abreviations:
CHO = carbohydrates,
%E = percent of total energy intake,
P/S = polyunsaturated / saturated fat ratio,
chol = cholesterol,
CVD = cardiovascular disease,
MI = myocardial infarction
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Characteristics of ongoing studies [ordered by study ID]
Canadian DBCP
Trial name or title
Methods
Participants women with mamographic densities >50% breast area (Canada
CVD risk: low
% men: 0
age: (all 30-65)
Interventions control: self-selected diet (no advice)
intervention: total fat 15%E, protein 20%E, CHO 65%E
style: diet advice
Outcomes Stated trial outcomes: incidence of breast cancer
Starting date 1994?
Contact information NFBoyd,Division of Epidemiology and Statistics, OntarioCancer Institute, 610University Avenue, Toronto,
Ontario, Canada M5G 2M9
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Canadian DBCP (Continued)
Notes
CARMEN
Trial name or title
Methods
Participants people with BMI 26-34 (Europe)
CVD risk: low
Interventions control: no advice or shop, no intervention or shop to attain national ”normal“ intake
intervention: Dietary advice and trial shop aims: total fat 10%E with varying ratios of refined to complex
CHO
style: dietary advice & supplement (shop)
Outcomes Stated trial outcomes: weight, body composition, lipids
Starting date 1996?
Contact information WHM Saris, Department of Human Biology, University of Maastricht, PO Box 616, NL-6200 MD, The
Netherlands
Notes
Polyp Prevention
Trial name or title
Methods
Participants people with at least one adenomatous polyp of the large bowel removed (USA)
CVD risk: low
% male: 65
age: mean 65 (all at least 35)
Interventions control: general dietary guidelines
intervention: total fat 20%E, 18g fibre/1000kcal, 5-8 servings fruit and veg daily
style: diet advice
Outcomes Stated trial outcomes: recurrence of polyps
Starting date 1991
Contact information A Schatzkin, Department of Health and Human Services, Public Health Service, NIH, National Cancer
Institute, Bethesda MD 20892, USA
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Polyp Prevention (Continued)
Notes
WINS
Trial name or title
Methods
Participants women with localised breast cancer (USA)
CVD risk: low
% men: 0
age: mean 61 (all post-menopausal)
Interventions control: minimal nutritional counselling focussed on nutritional adequacy
intervention: total fat 15-20%E
style: dietary advice
Outcomes Stated trial outcomes: dietary fat intake, total cholesterol, weight and waist
Starting date 1990?
Contact information DP Rose, Division of Nutrition and Endocrinology, American Health Foundation, 1 Dana Road, Valhalla,
NY 10595 USA
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Outcome data from included trials [data as ’control / intervention’]
Included arm Initial CVD
risk
Person-yrs
obs.
No. random-
ized
Total mortal-
ity
CVD mortal-
ity
Comb. CVD
event
Events
included
BDIT Pilot
Studies
low 1138/986 147/148 3 (randomiza-
tion
uncertain)
DART high 1917/1925 1015/1018 113/111 100/101 147/136 CV deaths
(inc. stroke)
plus non-fatal
MI
Diet & Gall-
stones
low 10.3/10.9 17/19 0/0
German Fat
Reduced
low 25.1/26.3 35/35 0/0 0/0 0/0 CV deaths,
non-fatal MI,
stroke
Glasgow Diet
in HT
moderate 33.8/33.2 72/72 0/0 0/0 0/0 CV deaths
Glasgow
Weight Loss
low 22.4/24.4 53/57 0/0 0/0 0/0 CV
deaths, non fa-
tal MI, stroke
KentuckyLow
Fat
moderate 56.5/105 62/115 0/0 0/0 0/0 CV deaths, fa-
tal andnon-fa-
tal MI, stroke
Kuo-
pio Fat Modi-
fied (AHA)
moderate 6.2/20.5 12.3/41 0/0
Kuopio
Fat Mod. (low
fat)
moderate 6.2/20.0 12.3/40 0/0
Kuo-
pio Fat Modi-
fied (mono)
moderate 6.2/20.5 12.3/41 0/0
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Table 1. Outcome data from included trials [data as ’control / intervention’] (Continued)
Linoleic
Enrichment
moderate 40/34 20/18 0/0 0/0 0/0 CV deaths,
non-fatal MI,
stroke
London Corn
/Olive (Corn)
high 21.8/41.3 13/28 0.5/5 0.5/5 5.5/15 CV deaths,
non-fatal MI,
angina, stroke
London Corn
/Olive (Olive)
high 21.8/38.0 13/26 0.5/3 0.5/3 5.5/11 CV deaths,
non-fatal MI,
angina, stroke
London Low
Fat
high 393.5/373.9 129/123 24/20 20/17 42/38 CV deaths
plus non-fatal
MI
Low Fat in
Breast CA
low 171/170 96/98 (at least
2 deaths, ran-
domization
uncertain)
Mastopathy
Diet
low 4.5/5.0 10/11 0/0 0/0 0/0 CV deaths
Minnesota
Coronary
low 4715/4823 4516/4516 248/269 157/157 129/134 total MI plus
sudden death
plus stroke
MRC Soya high 715/751 194/199 31/28 25/27 74/62 cardiovascular
deaths and fa-
tal or non-fa-
tal MI
MSFAT low 55.9/59.4 120.5/120.5 0/0
National diet-
heart (Farib-
ault 1st, B)
low 18.2/52.5 19/56 0/0 0/0 fatal and non-
fatal MI, PV
events
National diet-
heart (Farib-
ault 1st, C)
low 18.2/49.0 19/54 0/0 0/0 fatal and non-
fatal MI, PV
events
National diet-
heart (Farib-
ault 1st, E)
low 18.2/53.5 19/57 0/0 0/0 fatal and non-
fatal MI, PV
events
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Table 1. Outcome data from included trials [data as ’control / intervention’] (Continued)
National diet-
heart (open
1st, B)
low 120.5/358.5 127.3/385 0/0 0.3/0 fatal and non-
fatal MI, PV
events
National diet-
heart (open
1st, C)
low 120.5/361.0 127.3/390 0/0 0.3/4 fatal and non-
fatal MI, PV
events
National diet-
heart (open
1st, X)
low 120.5/50.0 127.3/54 0/0 0.3/1 fatal and non-
fatal MI, PV
events
National diet-
heart (open
2nd, BC)
low 58.8/112.5 101.3/194 0/0 1.3/0 fatal and non-
fatal MI, PV
events
National diet-
heart (open
2nd, F)
low 58.8/73.7 101.3/127 0/0 1.3/1 fatal and non-
fatal MI, PV
events
National diet-
heart (open
2nd, G)
low 58.8/69.6 101.3/120 0/0 1.3/0 fatal and non-
fatal MI, PV
events
National diet-
heart (open
2nd, X)
low 22/22 38/38 0/0 0/0 fatal and non-
fatal MI, PV
events
Oslo Diet-
Heart
high 885/895 206/206 65/48 52/38 91/66 total MI, sud-
den death,
stroke, angina
Oxford
Retinopathy
moderate 1160/1160 125/125 (34 deaths,
random-
ization uncer-
tain)
Sollentuna
Diet
moderate 19.5/20.0 40/40 0/0 0/0 0/0 total MI, CV
deaths, stroke
Stanford
Weight
low 42/42 44/45 0/0 0/0 0/0 CV deaths
STARS high 87.8/91.0 30/30 3/1 3/1 20/8 CV deaths,
non-fatal MI,
angina, stroke,
CABG, angio-
plasty
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Table 1. Outcome data from included trials [data as ’control / intervention’] (Continued)
Sydney Diet-
Heart
high 1011/939 237/221 28/39
Toronto Polyp
Prevention
low 204/198 102/99 0/0 0/0 0/0 CV deaths
Turku Weight
(mixed)
low 21.5/41.5 22/46 0/0 0/0 0/0 CV deaths, to-
tal MI,
angina, stroke,
heart failure,
angioplasty or
CABG
Turku Weight
(vegetarian)
low 21.5/38.5 22/46 0/0 0/0 0/0 CV deaths, to-
tal MI,
angina, stroke,
heart failure,
angioplasty or
CABG
Veterans Ad-
ministration
low 1544/1588 422/424 177/174 59/44 122/97 sudden
death, definite
MI, definite
stroke, angina,
PV events
Veterans Diet
& Skin CA
low 125/123 67/66 2/1 2/0 2/0 CV deaths
Total, all trials 15,096/15,
806 (30,902)
8647/9549
(18,196)
692/699
(1430)
419/393
(812)
643/573
(1216)
Total, high
risk trials
5053/5054
(10,107)
1837/1851
(3688)
265/255
(520)
201/192
(393)
385/336
(721)
Table 2. Results of random effects meta-analyses and subgrouping
Analysis described Outcome Rate ratio 95% C.I. Effect significant? Heterogeneity?
Meta-analysis total mortality 0.98 0.86 to 1.12 no not significant (chi-square
= 11.9 on 10 degrees of
freedom, p=0.298)
Meta-analysis cardiovascular mor-
tality
0.91 0.77 to 1.07 no not significant (chi-square
= 10.4 on 9 degrees of free-
dom, p=0.319)
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Table 2. Results of random effects meta-analyses and subgrouping (Continued)
Meta-analysis combined cardio-
vascular events
0.84 0.719 to 0.986 yes, significant protective
effect of the intervention
not significant (chi-square
= 20.4 on 15 degrees of
freedom, p=0.159)
Meta-analysis, sub-
group ’mean follow-
up 2 years or less’
total mortality 1.04 0.90 to 1.21 no not significant (chi-square
= 4.1 on 4 degrees of free-
dom, p=0.396)
Meta-analysis, sub-
group ’mean follow-
up more than 2
years’
total mortality 0.93 0.75 to 1.15 no not significant (chi-square
= 6.8 on 5 degrees of free-
dom, p=0.237)
Meta-analysis, sub-
group ’low cardio-
vascular risk’
total mortality 1.01 0.89 to 1.16 no not significant (chi-square
= 1.0 on 2 degrees of free-
dom, p=0.602)
Meta-analysis, sub-
group ’high cardio-
vascular risk’
total mortality 0.97 0.76 to 1.25 no not significant (chi-square
= 10.6 on 7 degrees of free-
dom, p=0.155)
Meta-analysis, sub-
group ’diet advice
only’
total mortality 1.03 0.79 to 1.34 no not significant (chi-square
= 4.7 on 4 degrees of free-
dom, p=0.324)
Meta-analysis, sub-
group ’diet advice
plus supplement’
total mortality 0.92 0.57 to 1.50 no not significant (chi-square
= 4.9 on 3 degrees of free-
dom, p=0.177)
Meta-anal-
ysis, sub-group ’diet
provided’
total mortality 1.02 0.89 to 1.16 no not significant (chi-square
= 0.6 on 1 degree of free-
dom, p=0.451)
Meta-analysis, sub-
group ’mean follow-
up 2 years or less’
combined cardio-
vascular events
0.96 0.75 to 1.23 no not significant (chi-square
= 12.3 on 10 degrees of
freedom, p=0.269)
Meta-analysis, sub-
group ’mean follow-
up more than 2
years’
combined cardio-
vascular events
0.76 0.65 to 0.90 yes, significant protective
effect of the intervention
not significant (chi-square
= 4.0 on 4 degrees of free-
dom, p=0.405)
Meta-analysis, sub-
group ’low cardio-
vascular risk’
combined cardio-
vascular events
0.82 0.56 to 1.20 no not significant (chi-square
= 13.0 on 8 degrees of free-
dom, p=0.113)
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Table 2. Results of random effects meta-analyses and subgrouping (Continued)
Meta-analysis, sub-
group ’high cardio-
vascular risk’
combined cardio-
vascular events
0.84 0.70 to 0.99 yes, significant protective
effect of the intervention
not significant (chi-square
= 7.2 on 5 degrees of free-
dom, p=0.300)
Meta-analysis, sub-
group ’diet advice
only’
combined cardio-
vascular events
0.79 0.51 to 1.23 no not significant (chi-square
= 8.5 on 4 degrees of free-
dom, p=0.074)
Meta-analysis, sub-
group ’diet advice
plus supplement’
combined cardio-
vascular events
0.79 0.62 to 1.00 no not significant (chi-square
= 8.5 on 8 degrees of free-
dom, p=0.383)
Meta-anal-
ysis, sub-group ’diet
provided’
combined cardio-
vascular events
0.89 0.68 to 1.16 no not significant (chi-square
= 2.2 on 1 degree of free-
dom, p=0.136)
Table 3. Results of random effects meta-regression (rate ratio versus change in factor)
Analysis described Slope 95% C.I. Effect significant?
ln (rate ratio for total mortality)
versus difference in percentage
energy from fat
0.015 -0.009 to 0.039 no
ln (rate ratio for total mortality)
versus difference in serum total
cholesterol
0.297 -0.141 to 0.734 no
ln (rate ratio for combined car-
diovascular events) versus dif-
ference in percentage energy
from fat
0.004 -0.012 to 0.021 no
ln (rate ratio for combined car-
diovascular events) versus dif-
ference in serum total choles-
terol
0.296 -0.094 to 0.687 no
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WH A T ’ S N E W
Last assessed as up-to-date: 31 January 2000.
Date Event Description
9 September 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 2, 2000
Date Event Description
1 February 2000 New citation required and conclusions have changed Substantive amendment
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